PL3362098T3 - Sposób zmiany stanu funkcjonalnego mrna pozwalający na jego selektywne i swoiste rozpoznawanie - Google Patents

Sposób zmiany stanu funkcjonalnego mrna pozwalający na jego selektywne i swoiste rozpoznawanie

Info

Publication number
PL3362098T3
PL3362098T3 PL16845348.8T PL16845348T PL3362098T3 PL 3362098 T3 PL3362098 T3 PL 3362098T3 PL 16845348 T PL16845348 T PL 16845348T PL 3362098 T3 PL3362098 T3 PL 3362098T3
Authority
PL
Poland
Prior art keywords
selective
changing
way
functional state
individual recognition
Prior art date
Application number
PL16845348.8T
Other languages
English (en)
Inventor
Filip RÁZGA
Veronika NÉMETHOVÁ
Original Assignee
Filip RÁZGA
Veronika NÉMETHOVÁ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Filip RÁZGA, Veronika NÉMETHOVÁ filed Critical Filip RÁZGA
Publication of PL3362098T3 publication Critical patent/PL3362098T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183Diol linkers, e.g. glycols or propanediols
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/331Universal or degenerate base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16845348.8T 2015-10-15 2016-10-12 Sposób zmiany stanu funkcjonalnego mrna pozwalający na jego selektywne i swoiste rozpoznawanie PL3362098T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK50065-2015A SK500652015A3 (sk) 2015-10-15 2015-10-15 Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie
PCT/SK2016/060002 WO2017065696A2 (en) 2015-10-15 2016-10-12 A method for altering the functional state of mrna allowing its selective and specific recognition

Publications (1)

Publication Number Publication Date
PL3362098T3 true PL3362098T3 (pl) 2022-07-18

Family

ID=58267152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16845348.8T PL3362098T3 (pl) 2015-10-15 2016-10-12 Sposób zmiany stanu funkcjonalnego mrna pozwalający na jego selektywne i swoiste rozpoznawanie

Country Status (20)

Country Link
US (1) US11371038B2 (pl)
EP (1) EP3362098B1 (pl)
JP (3) JP7053473B2 (pl)
KR (1) KR102307184B1 (pl)
AU (1) AU2016336851B2 (pl)
CA (1) CA3001994A1 (pl)
CY (1) CY1125386T1 (pl)
DK (1) DK3362098T3 (pl)
ES (1) ES2920887T3 (pl)
HR (1) HRP20220968T1 (pl)
HU (1) HUE058829T2 (pl)
LT (1) LT3362098T (pl)
PL (1) PL3362098T3 (pl)
PT (1) PT3362098T (pl)
RS (1) RS63354B1 (pl)
RU (1) RU2724485C2 (pl)
SI (1) SI3362098T1 (pl)
SK (1) SK500652015A3 (pl)
SM (1) SMT202200319T1 (pl)
WO (1) WO2017065696A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2021002984A1 (en) * 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
CA3140438A1 (en) * 2019-06-05 2020-12-10 Masatora Fukuda Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
CA2103377A1 (en) * 1991-06-18 1992-12-19 Bruno Calabretta Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
EP0551294A4 (en) * 1991-08-01 1993-12-29 City Of Hope Ribozyme inhibition of bcr-abl gene expression
WO1994013793A1 (en) * 1992-12-04 1994-06-23 Apollon, Inc. Compounds and methods for the treatment of leukemias
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5747248A (en) * 1994-12-05 1998-05-05 Chiron Corporation Discontinuous probe design using hybritope mapping
US6458940B2 (en) * 1995-06-06 2002-10-01 Hybridon, Inc. HPV-specific oligonucleotides
EP0991777A1 (en) * 1997-06-18 2000-04-12 Ulrich J. Krull Nucleic acid biosensor diagnostics
FR2781802B1 (fr) * 1998-07-31 2001-05-11 Bio Merieux Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif
AP2002002638A0 (en) * 2000-03-27 2002-09-30 Univ Delaware Targeted chromosomal genomic alternations with modified single stranded oligonucleotides.
JP3728463B2 (ja) * 2001-10-11 2005-12-21 学校法人慶應義塾 新規マキシザイム
DE10202419A1 (de) * 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
AU2004206820B2 (en) 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
MXPA05011022A (es) * 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
MX2010001785A (es) 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
DK2470656T3 (da) 2009-08-27 2015-06-22 Idera Pharmaceuticals Inc Sammensætning til hæmning af genekspression og anvendelser heraf
US20130079505A1 (en) 2010-03-24 2013-03-28 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
KR101590586B1 (ko) * 2011-05-30 2016-02-01 성균관대학교산학협력단 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 rna
ES2578370T3 (es) * 2011-07-01 2016-07-26 HTG Molecular Diagnostics, Inc Métodos para detectar fusiones génicas
KR20150080417A (ko) * 2013-12-30 2015-07-09 경희대학교 산학협력단 링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도

Also Published As

Publication number Publication date
ES2920887T3 (es) 2022-08-11
SMT202200319T1 (it) 2022-09-14
RS63354B1 (sr) 2022-07-29
JP2018534945A (ja) 2018-11-29
JP7053473B2 (ja) 2022-04-12
KR20180084748A (ko) 2018-07-25
US11371038B2 (en) 2022-06-28
HRP20220968T1 (hr) 2022-10-28
LT3362098T (lt) 2022-06-27
NZ742493A (en) 2021-09-24
EP3362098A2 (en) 2018-08-22
AU2016336851A1 (en) 2018-06-07
AU2016336851B2 (en) 2020-06-18
US20180291366A1 (en) 2018-10-11
JP2025027114A (ja) 2025-02-26
WO2017065696A3 (en) 2017-07-06
EP3362098B1 (en) 2022-05-04
CY1125386T1 (el) 2024-09-20
RU2018117650A3 (pl) 2019-11-15
JP7657756B2 (ja) 2025-04-07
JP2022097486A (ja) 2022-06-30
WO2017065696A2 (en) 2017-04-20
PT3362098T (pt) 2022-06-06
CA3001994A1 (en) 2017-04-20
RU2018117650A (ru) 2019-11-15
SK500652015A3 (sk) 2017-05-03
SI3362098T1 (sl) 2022-08-31
RU2724485C2 (ru) 2020-06-23
KR102307184B1 (ko) 2021-10-01
HUE058829T2 (hu) 2022-09-28
DK3362098T3 (da) 2022-07-18

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
IL282048A (en) Oxysterols and methods of use thereof
IL258437B (en) Growing systems and methods
IL259766B (en) Relocalization systems and methods
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3529683A4 (en) MULTICOPTERS WITH PUSHED VECTOR
KR20180084972A (ko) 조명 및 사운드 시스템
PL3363732T3 (pl) Konfiguracja wyrzutnika i płata
IL255238B (en) Combinations of cannabinoids and n-acylethanolamines
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3314343T3 (pl) Osobiste drony sensoryczne
EP3380080A4 (en) TOPICAL FILM-MAKING SPRAY
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
CL2018000700A1 (es) Sililfenoxiheterociclos trisustituidos y análogos
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
EP3350489A4 (en) VALVE AND COUPLING
DK3245331T3 (da) Fortøjningselement
EP3619321A4 (en) DP04 TYPE POLYMERASE VARIANTS
PT3389873T (pt) Escoamento turbulento de fragmentação controlada
DK3334576T3 (da) Stavelement
IL258856A (en) Solabegron zwitterion and uses thereof
PT3337506T (pt) Combinações e suas utilizações
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도